SG175570A1 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations Download PDF

Info

Publication number
SG175570A1
SG175570A1 SG2011070588A SG2011070588A SG175570A1 SG 175570 A1 SG175570 A1 SG 175570A1 SG 2011070588 A SG2011070588 A SG 2011070588A SG 2011070588 A SG2011070588 A SG 2011070588A SG 175570 A1 SG175570 A1 SG 175570A1
Authority
SG
Singapore
Prior art keywords
salt
fenofibric acid
temperature
formulation
active agent
Prior art date
Application number
SG2011070588A
Other languages
English (en)
Inventor
Yi Gao
R Ju Tzuchi
Dennis Y Lee
Nicole Nguyen
Hauiliang Wu
Original Assignee
Abbott Lab
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Fournier Lab Ireland Ltd filed Critical Abbott Lab
Publication of SG175570A1 publication Critical patent/SG175570A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG2011070588A 2006-10-12 2007-10-12 Pharmaceutical formulations SG175570A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82925506P 2006-10-12 2006-10-12

Publications (1)

Publication Number Publication Date
SG175570A1 true SG175570A1 (en) 2011-11-28

Family

ID=38961056

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011070588A SG175570A1 (en) 2006-10-12 2007-10-12 Pharmaceutical formulations

Country Status (14)

Country Link
EP (1) EP2081563A1 (enExample)
JP (1) JP2010506855A (enExample)
KR (1) KR20090119959A (enExample)
CN (1) CN101677981A (enExample)
AU (1) AU2007307641A1 (enExample)
CA (1) CA2672686A1 (enExample)
CO (1) CO6160302A2 (enExample)
EA (1) EA200900531A1 (enExample)
EC (1) ECSP099251A (enExample)
IL (1) IL198160A0 (enExample)
MX (1) MX2009003815A (enExample)
SG (1) SG175570A1 (enExample)
WO (1) WO2008046052A1 (enExample)
ZA (1) ZA200902488B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285357B8 (en) * 2008-05-30 2014-07-23 UCB Pharma, S.A. Pharmaceutical compositions comprising brivaracetam
CN102304103A (zh) * 2011-06-03 2012-01-04 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸盐、制备方法、药物组合物及应用
CN102659570B (zh) * 2012-05-17 2014-05-28 安润医药科技（苏州）有限公司 二氟非诺贝特酸及其在药学上可接受的盐，以及它们的制备方法和应用
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1832285A1 (en) * 2002-12-17 2007-09-12 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
MX2007012443A (es) * 2005-04-08 2007-12-13 Abbott Lab Formulaciones farmaceuticas orales que comprenden acido fenofibrico y/o sus sales.

Also Published As

Publication number Publication date
IL198160A0 (en) 2009-12-24
CO6160302A2 (es) 2010-05-20
CN101677981A (zh) 2010-03-24
JP2010506855A (ja) 2010-03-04
AU2007307641A1 (en) 2008-04-17
ECSP099251A (es) 2009-06-30
MX2009003815A (es) 2009-09-07
EA200900531A1 (ru) 2009-12-30
KR20090119959A (ko) 2009-11-23
WO2008046052A1 (en) 2008-04-17
CA2672686A1 (en) 2008-04-17
EP2081563A1 (en) 2009-07-29
ZA200902488B (en) 2010-10-27

Similar Documents

Publication Publication Date Title
US20130085181A1 (en) Pharmaceutical formulations
RU2743637C2 (ru) Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице
JP5816091B2 (ja) ナトリウムオキシベートの即時放出投薬形態
US8709996B2 (en) Pharmaceutical treatment process using chitosan or derivative thereof
JP5517932B2 (ja) ラモトリジンの改良製剤
US11291660B2 (en) Method of treating heart failure with preserved ejection fraction by administering milrinone
JP2012514623A (ja) １またはそれ以上のフマル酸エステルを含む医薬組成物
CA2604078A1 (en) Enteric pharmaceutical formulations of choline salt of fenofibric acid
JP2009501801A (ja) イブプロフェンとファモチジンとを含有する医薬およびその投与
JP2009517346A5 (enExample)
AU2007307641A1 (en) Pharmaceutical formulations
IL192091A (en) Sustained release pharmaceutical compositions comprising liothyronine, process for their preparation and their use in the manufacture of medicaments
Säkkinen et al. In vivo evaluation of matrix granules containing microcrystalline chitosan as a gel-forming excipient
CN115721600B (zh) 一种胃滞留型普瑞巴林缓释组合物及其制备方法
JP2013542974A (ja) 重炭酸塩を含んでなる医薬組成物、並びに尿路結石症及び関連疾患の治療及び／又は予防における医薬としてのこれらの使用
Nykänen et al. Citric acid as a pH-regulating additive in granules and the tablet matrix in enteric-coated formulations for colon-specific drug delivery
NZ732954B2 (en) Method of Treating Heart Failure with Preserved Ejection Fraction with 5-(Pyridinyl)-2(1H)-pyridinone Compounds
EA042106B1 (ru) Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице